HKI-357 is an investigational drug.
There have been 22 clinical trials for HKI-357.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 9th 2009.
The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Puma Biotechnology, Inc., Wyeth is now a wholly owned subsidiary of Pfizer, and NSABP Foundation Inc.